DNA

Angle PLC Announces Trading and Business Update

Revenue recognised for 2023 expected to be up 120% at c. £2.2 million with sales secured in 2023 expected to…

8 months ago

Medidata Announces New Data Integration Solutions to Accelerate Clinical Trials: Clinical Data Studio and Health Record Connect

Adding to Medidata’s already extensive platform, Medidata Clinical Data Studio and Medidata Health Record Connect usher in a new era…

8 months ago

Prime Medicine to Present at Upcoming Investor Conferences

Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a…

8 months ago

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

8 months ago

SENATE MOVES TO END RAPE KIT BACKLOG: Votes to Renew Debbie Smith Act-Most Effective Anti-Rape Legislation

Washington, D.C.--(Newsfile Corp. - November 6, 2023) - The U.S. Senate voted to renew the Debbie Smith Act, a law…

8 months ago

The Fourth Edition of the Longevity Investors Conference, Held in Gstaad (Switzerland), Unites Visionary Scientists, Industry Titans and Investors for Unprecedented Collaboration

The two full day event, Longevity Investors Conference, held in Gstaad, featured a diverse array of speakers, including leading scientists,…

8 months ago

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE…

8 months ago

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Data further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cellsBOSTON, Nov. 04, 2023…

8 months ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology…

9 months ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety…

9 months ago